Literature DB >> 19555824

Medical treatment of Parkinson disease.

Mark Stacy1.   

Abstract

The cardinal characteristics of Parkinson disease (PD) include resting tremor, rigidity, and bradykinesia. Patients may also develop autonomic dysfunction, cognitive changes, psychiatric symptoms, sensory complaints, and sleep disturbances. The treatment of motor and non-motor symptoms of Parkinson disease is addressed in this article.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19555824     DOI: 10.1016/j.ncl.2009.04.009

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  15 in total

1.  Intraoperative acceleration measurements to quantify improvement in tremor during deep brain stimulation surgery.

Authors:  Ashesh Shah; Jérôme Coste; Jean-Jacques Lemaire; Ethan Taub; W M Michael Schüpbach; Claudio Pollo; Erik Schkommodau; Raphael Guzman; Simone Hemm-Ode
Journal:  Med Biol Eng Comput       Date:  2016-09-08       Impact factor: 2.602

2.  Effects of Non-Pharmacological Treatments on Quality of Life in Parkinson's Disease: A Review.

Authors:  Sangwoo Ahn; Yan Chen; Tim Bredow; Corjena Cheung; Fang Yu
Journal:  J Parkinsons Dis Alzheimers Dis       Date:  2017-04-20

Review 3.  Progression of motor symptoms in Parkinson's disease.

Authors:  Ruiping Xia; Zhi-Hong Mao
Journal:  Neurosci Bull       Date:  2012-02       Impact factor: 5.203

4.  Acute administration of L-DOPA induces changes in methylation metabolites, reduced protein phosphatase 2A methylation, and hyperphosphorylation of Tau protein in mouse brain.

Authors:  Teodoro Bottiglieri; Erland Arning; Brandi Wasek; Viyada Nunbhakdi-Craig; Jean-Marie Sontag; Estelle Sontag
Journal:  J Neurosci       Date:  2012-07-04       Impact factor: 6.167

Review 5.  Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's Disease.

Authors:  Daphne Robakis; Stanley Fahn
Journal:  CNS Drugs       Date:  2015-06       Impact factor: 5.749

Review 6.  Non-human primate models of PD to test novel therapies.

Authors:  Marc Morissette; Thérèse Di Paolo
Journal:  J Neural Transm (Vienna)       Date:  2017-04-08       Impact factor: 3.575

Review 7.  Available and emerging treatments for Parkinson's disease: a review.

Authors:  Patrick Hickey; Mark Stacy
Journal:  Drug Des Devel Ther       Date:  2011-05-02       Impact factor: 4.162

8.  Hypersynchrony despite pathologically reduced beta oscillations in patients with Parkinson's disease: a pharmaco-magnetoencephalography study.

Authors:  Elizabeth Heinrichs-Graham; Max J Kurz; Katherine M Becker; Pamela M Santamaria; Howard E Gendelman; Tony W Wilson
Journal:  J Neurophysiol       Date:  2014-07-09       Impact factor: 2.714

Review 9.  Adenosine A2A antagonists in Parkinson's disease: what's next?

Authors:  Patrick Hickey; Mark Stacy
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

Review 10.  Deep Brain Stimulation: A Paradigm Shifting Approach to Treat Parkinson's Disease.

Authors:  Patrick Hickey; Mark Stacy
Journal:  Front Neurosci       Date:  2016-04-28       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.